StockWatch
·

Monte Rosa Therapeutics, Inc. Q2 FY26 Results

GLUEQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue8.97113.1%61.3%
Total Income8.97113.1%61.3%
Expenditure58.107.1%49.9%
PBT-43.192.8%289.1%
Net Profit-43.402.5%252.8%
OPM—
NPM—
EPS—
View full financials

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

06 Aug 2026 · 6 Aug, 4:38 pm

Summary

Monte Rosa Therapeutics reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in its clinical-stage portfolio. The company ended the quarter with a strong balance sheet, holding $626.0 million in cash, cash equivalents, restricted cash, and marketable securities, which is expected to fund operations into 2029. Key business updates include the completion of enrollment for the GFORCE-1 study of MRT-8102 and the activation of several Phase 2 studies for MRT-8102 and MRT-2359. The company anticipates a catalyst-rich second half of 2026, with anticipated readouts and study initiations across its pipeline.

Key Highlights

  1. 1

    Monte Rosa Therapeutics announced its financial results for the second quarter ended June 30, 2026.

  2. 2

    The company reported a strong balance sheet with cash, cash equivalents, restricted cash, and marketable securities of $626.0 million, expected to support operations into 2029.

  3. 3

    Enrollment and dosing for the GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk have been completed, with a readout anticipated in H2 2026.

  4. 4

    The company expects to initiate multiple MRT-8102 Phase 2 studies in H2 2026 and H1 2027 across various indications including atherosclerotic risk, cardiometabolic syndrome, gout flares, and hidradenitis suppurativa.

  5. 5

    The MODeFIRe-1 Phase 2 study of MRT-2359, in combination with apalutamide in metastatic castration-resistant prostate cancer patients (mCRPC) with androgen receptor (AR) mutations, has been activated.

  6. 6

    The Phase 2a/b clinical trial for VAV1-directed MGD MRT-6160 (DDY391) has been activated in participants with Sjögren’s disease, conducted by Novartis.

  7. 7

    Monte Rosa expects to provide an update on the initial Phase 1/2 expansion arm exploring MRT-2359 in advanced CRPC by the end of the year.

Management Comments

M

Markus Warmuth

We’re tremendously proud of our progress to date in 2026, defined by strong execution across our clinical-stage portfolio, with two Phase 2 trials activated and additional trials expected across our programs. Importantly, for our VAV1 program, Novartis recently activated a Phase 2 study evaluating MRT-6160 (DDY391) in individuals with Sjögren’s disease, representing an important step forward for this program and established collaboration. We look forward to additional Phase 2 study activations expected as part of a broader development effort to evaluate the potential of MRT-6160 across other immune-mediated diseases. In addition, the Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations is now activated, and we expect to enroll our first patients imminently, positioning us to validate the strong signals of clinical activity we observed in this patient population in our Phase 1/2 trial. We will update data from the initial Phase 1/2 arm exploring MRT-2359 in advanced CRPC by the end of the year. Moving forward, we expect a catalyst-rich second half of 2026, including data from our GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease risk, the study having been fully enrolled in June. With these data, we look forward to deepening our understanding of MRT-8102’s clinical activity across multiple dose levels and its impact on inflammatory and cardiometabolic biomarker endpoints. In particular, we will present data on levels of damage-associated molecular patterns (DAMPs) such as calprotectin that promote local inflammation, atherosclerotic plaque instability, and rupture of plaques in individuals with ASCVD – processes not adequately addressed by IL-1/IL-6 antibodies – as well as pathologic cytokines and C-reactive protein (CRP), a well-established pharmacodynamic marker. Over the next 9 to 12 months, we expect to initiate three MRT-8102 Phase 2 studies, including our Phase 2b study, GFORCE-2, later this year, which will inform the potential of MRT-8102 to modulate key parameters of metabolic and atherosclerotic risk, liver inflammation and anemia of inflammation through both primary and secondary study endpoints, as well as GEMINI-1, our study to explore the potential of MRT-8102 to prevent recurrent gout flares following management of acute flares. In summary, we continue to be impressed by the potential of MRT-8102 to address sterile inflammation in a variety of disorders with high unmet medical need, and we continue to explore multiple promising development opportunities in that space.

Informational and educational content only. Not investment advice.